Navigation Links
Delcath Systems, Inc. Secures $20 Million Credit Facility
Date:4/23/2012

w hemofiltration cartridge,  the timing of the supply and distribution of the CHEMOSAT system including the new hemofiltration cartridge to early launch centers Europe,  the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relating to the results of research and development projects and future clinical trials, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.Contact Informa
'/>"/>
SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. Delcath Systems, Inc. Completes Phase III Study Enrollment
10. Delcath Systems Begins Data Analysis of Phase III Trial
11. Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 Egalet ... integrated specialty pharmaceutical company focused on developing, manufacturing ... closing of its previously announced underwritten public offering ... a public offering price of $11.25 per share. ... included 1,000,000 shares issued upon the exercise in ...
(Date:7/31/2015)... Calif. , July 31, 2015  Xencor, Inc. ... engineered monoclonal antibodies for the treatment of autoimmune diseases, ... appointment of Yujiro S. Hata to its ... experience in business and corporate development is a tremendous ... Ph.D., president and chief executive officer of Xencor. "Xencor ...
(Date:7/30/2015)... 2015 Edwards Lifesciences Corporation (NYSE: EW ), ... hemodynamic monitoring, today announced that Robert A. Ingram ... "Bob is an ardent champion for innovation in the lifesciences ... him on Edwards, board as we pursue our focused innovation ... CEO.  "Bob has provided a valuable perspective to our board, ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... Inc. (NYSE: PFE ) announced today that based on discussions ... commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) (used for the treatment ... and that it will be voluntarily withdrawing the new drug application (NDA) ... , , ...
... , June 21 Celator Pharmaceuticals today announced that ... The research agreement provides for the utilization of Celator,s proprietary technology ... , , , ... are pleased that work with this research program has led to ...
Cached Medicine Technology:Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 2Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 3Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 4Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 5Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 6Celator® Pharmaceuticals Expands Research Agreement With Cephalon, Inc. 2Celator® Pharmaceuticals Expands Research Agreement With Cephalon, Inc. 3
(Date:8/1/2015)... ... 01, 2015 , ... Tina Wilcoxson, owner of Freeport Maine’s Royal River Natural ... by the National Retail Federation, the largest retail trade association in the world, for ... business owners to be named as such. According to the NRF’s website, Retail Champions ...
(Date:8/1/2015)... ... August 01, 2015 , ... Professional ... portfolio company has acquired Premier Physical Therapy & Wellness (“Premier”) — with 13 ... state-of-the-art clinics. , “Our acquisition of Premier Physical Therapy & Wellness solidifies Professional ...
(Date:8/1/2015)... ... 01, 2015 , ... Lume Wellness creators Alex, Robert, and Sam have announced ... Apple AppStore. , The app is designed to track various metrics of wellness, ... to view personal health and use this information for positive behavior modification. Lume Wellness ...
(Date:8/1/2015)... ... ... reTXT ” was featured on NewsWatch as part of its monthly AppWatch, which takes ... and Windows. Joe Toohey, the host of AppWatch and technology expert, conducted the app ... including ones already sent. , While text messaging has more features than it did ...
(Date:7/31/2015)... ... July 31, 2015 , ... That’s right, the ... the STASH awards? The Significant Technological Achievements in Secretive Horticulture (or STASH) Awards, ... as tried-and-true products that have stood the test of time. These include lighting ...
Breaking Medicine News(10 mins):Health News:Local Retail Advocate Wins National Recognition 2Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2
... 10, 2011 Researchers at UT Southwestern Medical Center have ... drug that fights cancers that are dependent on a particular ... compound,s effectiveness at fighting tumors in mice. If it is ... on the compound to combat pancreatic and non-small cell lung ...
... Revises "McDonald Criteria" for Diagnosing MS -- Use of ... MS Awareness Week An international panel has revised ... multiple sclerosis, incorporating new data that should speed the ... of MS, organized and supported by the National MS ...
... , WEDNESDAY, March 9 (HealthDay News) -- Drinking ... the risk for developing both Alzheimer,s and some forms ... noting that full-fledged alcohol abuse accounts for about 10 ... consumption of just one to two drinks a ...
... Despite dramatically improved survival rates for childhood acute lymphoblastic ... from the disease. Work led by St. Jude Children,s ... CREBBP that may help the cancer resist steroid treatment ... role in normal blood cell development, helping to switch ...
... March 2011 The Nobel prize-winning physicist Richard Feynman once ... other people think?): "When I see equations, I see letters ... wonder what the hell it must look like to the ... and Feynman,s experience of "seeing" the letters in colour was ...
... Human social interactions are shaped by our ability to recognise ... the key features that enable us to identify individual people, ... and body size, that lead to a unique identity for ... has already determined the various brain regions responsible for face ...
Cached Medicine News:Health News:Researchers develop synthetic compound that may lead to drugs to fight pancreatic, lung cancer 2Health News:International panel revises 'McDonald Criteria' for diagnosing multiple sclerosis 2Health News:International panel revises 'McDonald Criteria' for diagnosing multiple sclerosis 3Health News:International panel revises 'McDonald Criteria' for diagnosing multiple sclerosis 4Health News:International panel revises 'McDonald Criteria' for diagnosing multiple sclerosis 5Health News: A Little Alcohol May Stave Off Alzheimer's 2Health News:When leukemia returns, gene that mediates response to key drug often mutated 2Health News:When leukemia returns, gene that mediates response to key drug often mutated 3Health News:Reading in 2 colours at the same time 2Health News:How do we combine faces and voices? 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: